Please assess the completion status of the following clinical trial:

Trial Title: The Effects of RPL554 in Addition to Tiotropium in COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Sign an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.~2. Male or female aged between 40 and 75 years inclusive, at the time of informed consent.~3. If male: must agree to meet the following from the first dose up to 1 month after the last dose of study treatment:~   * Not donate sperm~  * Either: be sexually abstinent in accordance with a patient's usual and preferred lifestyle (but agree to abide by the contraception requirements below should their circumstances change) Or: use a condom with all sexual partners. If the partner is of childbearing potential the condom must be used with spermicide and a second highly effective form of contraception must also be used~4. If female: either be:~   1. Of non-childbearing potential defined as being:~      * Either: post-menopausal (being spontaneously amenorrhoeic for at least 1 year with an appropriate clinical profile \[e.g. age appropriate, history of vasomotor symptoms\]~     * Or: permanently sterilised e.g. tubal occlusion, hysterectomy, bilateral oophorectomy, bilateral salpingectomy~  2. Of childbearing potential and agreeing to use a highly effective method of contraception until completion of the end of study visit.~5. Have a 12-lead ECG recording at screening and randomisation (pre-dose in Treatment Period 1) showing the following:~   * Heart rate between 45 and 90 beats per minute (bpm)~  * QT interval corrected for heart rate using Fridericia's formula (QTcF) ≤450 msec for males and ≤470 ms for females~  * QRS interval ≤120 msec~  * No clinically significant abnormalities (as judged by the Investigator) including morphology (e.g. left bundle branch block, atrio-ventricular nodal dysfunction, ST segment abnormalities)~6. Have a screening Holter report with a minimum of 18 hours recording that is able to be evaluated for rhythm analysis which shows no abnormality which indicates a significant impairment of patient safety or which may significantly impairs interpretation in the opinion of the Investigator including:~   * Significant arrhythmias including atrial flutter, atrial fibrillation, ventricular tachycardia~  * Any symptomatic arrhythmia (except isolated extra systoles)~  * Any sustained second or third degree heart block~7. Capable of complying with all study restrictions and procedures including ability to use the study nebuliser and HandiHaler® DPI correctly.~8. Body mass index (BMI) between 18 and 33 kg/m2 (inclusive) with a minimum weight of 45 kg.~9. COPD diagnosis: Patients with a diagnosis of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines (Celli and MacNee, 2004) with symptoms compatible with COPD for at least 1 year prior to screening.~10. Post-bronchodilator (four puffs of salbutamol) spirometry at screening:~    * Post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio of ≤0.70~   * Post-bronchodilator FEV1 ≥40 % and ≤80% of predicted normal~   * Demonstrates ≥150 mL increase from pre-bronchodilator FEV1~11. Clinically stable COPD in the 4 weeks prior to screening and randomisation (pre-dose in Treatment Period 1).~12. A chest X-ray (post-anterior) at screening, or in the 12 months prior to screening showing no abnormalities, which are both clinically significant and unrelated to COPD.~13. Meet the concomitant medication restrictions and be expected to do so for the rest of the study.~14. Smoking history of ≥10 pack years.~15. Capable of withdrawing from long acting bronchodilators for the duration of the study, and short acting bronchodilators for 8 hours prior to spirometry.~Exclusion Criteria:~1. A history of life-threatening COPD exacerbation including Intensive Care Unit admission and/or requiring intubation.~2. COPD exacerbation requiring oral steroids, or lower respiratory tract infection requiring antibiotics, in the 3 months prior to screening or randomisation (pre-dose in Treatment Period 1).~3. A history of one or more hospitalisations for COPD in the 12 months prior to screening or randomisation (pre-dose in Treatment Period 1).~4. Lactation (female patients only).~5. Positive urine or serum pregnancy test at screening, or a positive urine pregnancy test prior to randomisation (female patients of childbearing potential only).~6. Prior exposure to RPL554 or known hypersensitivity to RPL554 or its components.~7. Intolerance or hypersensitivity to tiotropium.~8. Evidence of cor pulmonale.~9. Other respiratory disorders: Patients with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnoea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.~10. Previous lung resection or lung reduction surgery.~11. Use of oral COPD medications (e.g. oral steroids, theophylline and romifulast) in the 3 months prior to screening or randomisation (pre-dose in Treatment Period 1).~12. History of, or reason to believe, a patient has drug or alcohol abuse within the past 3 years.~13. Inability to perform technically acceptable spirometry or whole body plethysmography (at screening or randomisation \[pre dose in Treatment Period 1\])~14. Received an experimental drug within 30 days or five half lives, whichever is longer.~15. Patients with a history of chronic uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, haematological, urological, immunological, or ophthalmic diseases that the Investigator believes are clinically significant.~16. Documented cardiovascular disease: arrhythmias, angina, recent or suspected myocardial infarction, congestive heart failure, a history of unstable, or uncontrolled hypertension, or has been diagnosed with hypertension in the 3 months prior to screening or randomisation.~17. Concurrent use of non-cardioselective oral beta-blockers.~18. Has had major surgery, (requiring general anaesthesia) in the 6 weeks prior to screening or randomisation (pre-dose in Treatment Period 1), or will not have fully recovered from surgery, or planned surgery through the end of the study.~19. A disclosed history or one known to the Investigator, of significant non compliance in previous investigational studies or with prescribed medications.~20. Requires oxygen therapy, even on an occasional basis.~21. Clinically significant prostatic hyperplasia (judged by the Investigator) or bladder-neck obstruction or with narrow-angle glaucoma.~22. Any other reason that the Investigator considers makes the patient unsuitable to participate.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lower Dose Nebulised Treatment (Type: EXPERIMENTAL): 1.5 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
- Higher Dose Nebulised Treatment (Type: EXPERIMENTAL): 6 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
- Placebo (Type: PLACEBO_COMPARATOR): Nebulised RPL554 matched placebo twice daily plus 10 mcg tiotropium DPI once daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).